Introduction: Decoy receptor 3 (DcR3) has shown utility as a reliable surrogate marker. Levels of DcR3 in the serum increase and remain elevated in several disease states including cancer and sepsis. In inflammatory conditions, DcR3 is upregulated in inflammatory cells to suppress exponential immune propagation. The use of DcR3 as an indication of sepsis has been documented in the antemortem setting, but its use in the postmortem setting is unknown. The purpose of this study is to evaluate postmortem DcR3 as a marker of antemortem sepsis.
INTRODUCTION
The transition of the human body from antemortem to postmortem is not defined by a single point in time. Even when all macroscopic signs of life cease, the body's chemical makeup continues to evolve and promotes the production and destruction of numerous proteins, hormones, and metabolites. For that reason, ongoing clinical chemical research in the antemortem realm remains a rich source of potential postmortem investigative innovations.
In this study, we chose to investigate the potential clinical biomarker decoy receptor 3 (DcR3), in the identification of sepsis-related death. Decoy receptor 3 has recently shown utility as a reliable surrogate marker for patients with underlying bacterial sepsis in the clinical setting. It is a soluble, glycosylated protein and a member of the TNF receptor superfamily (1) . First discovered in the sera of patients with various malignancies, increased DcR3 levels have recently been observed in several disease states including autoimmune diseases, chronic infections, idiopathic pulmonary fibrosis, and bacterial sepsis (2) . Its exact physiological role is not fully understood, as DcR3 expression in physically healthy individuals is normally undetectable (3, 4) . In disease states, DcR3 is believed to regulate immune suppression by blocking the efficacy of three proapoptotic cytokines, fas ligand, homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes, and vascular endothelial growth inhibitor (2) (3) (4) . This results in multiple downstream effects (Figures 1 and 2 ) (3) (4) (5) . In inflammatory conditions such as sepsis, DcR3 is upregulated by monocytes and dendritic cells reacting to lipoteichoic acid and lipopolysaccharide components of gram-positive and gram-negative bacteria, respectively (1, 6) .
The use of DcR3 as an indication of sepsis has been documented several times in the antemortem setting (1-3,5,7), but its potential use in the postmortem investigation is unknown. The purpose of this study is to evaluate whether DcR3 is detectible in the postmortem period and whether varying DcR3 levels can be correlated with specific causes of death.
METHODS

Sample Selection
Four cohorts were created from autopsy cases performed at the University of Wisconsin Hospital and Clinics, between 2014 and 2017. A retrospective investigation was performed using the electronic pathology database PowerPath (Sunquest Informational Systems), to identify patients whose primary cause of death was attributed to carcinoma, culture-positive sepsis, or suspected (culture negative) sepsis. The final control cohort consisted of patients who did not show any indication of underlying carcinoma or sepsis at the time of death or subsequent autopsy.
Blood samples collected in sodium fluoride, or serum separator vacutainers at the time of autopsy, were retrieved from −20°C storage. Consent was obtained from next of kin at the time of autopsy for storage and use of patient samples for future research purposes per institutional guidelines. The samples were warmed and separated using centrifugation. The resulting serum was aliquoted into individually numbered plastic vials.
Testing
Levels of DcR3 were measured by quantitative enzyme-linked immunosorbent assay (ELISA) using a commercially available assay kit, the DuoSet ELISA System for human DcR3/TNFRSF6B, from R&D Systems (Minneapolis, MN). The sera samples were diluted 1:1 ratio with reagent dilute solution. One hundred microliters of each diluted sample was then added in duplicate to consecutive wells of 96-well microtiter plates. A standard curve was generated with known concentrations of recombinant human DcR3 in duplicate. Incubation and washing steps were performed per manufacturer's instructions. Immunoreactivity was quantified by biotin-streptavidin reaction and read on a spectrophotometer at 450 nm. The optical density of sample wells was used to calculate 
Statistics
The statistical analysis was performed using Microsoft Excel (Microsoft Office 2007, Redmond, Washington). Comparisons between the four cohorts were performed by single-factor analysis of variance, with comparisons between individual cohorts performed by two-sample t tests. The probability of the length of time until autopsy impacting DcR3 levels was calculated using a χ 2 test.
RESULTS
Cohorts
Sera from 47 autopsy cases were obtained from the University of Wisconsin Hospital and Clinics autopsy department. Patient demographics of each cohort are shown in Table 1 . All data concerning patients' underlying health status were retroactively retrieved from autopsy reports. Patients within the carcinoma cohort had a reported cause of death due to complications of severe or metastatic disease, with no evidence of underlying infection. Patients within the culture-positive cohort had a reported cause of death as secondary to sepsis with positive antemortem or postmortem cultures. Table 2 lists all of the observed carcinomas and cultured organisms from the aforementioned cohorts. The suspected (culture negative) negative cohort consisted of patients whose cause of death was reported as suspected (culture negative) sepsis based off of clinical criteria at the time of death and who had no other definitive causes of death or underlying carcinoma. These patients had no definitive source of infection at the time of autopsy, but did show signs of possible infection-related organ damage. Finally, the control cohort consisted of patients whose causes of death were mainly due to acute or chronic cardiovascular or cardiac disease, with two exceptions. One death was due to multiple blunt force injuries after a fall and the second death was due to massive, acute pulmonary embolism. 
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Presence of DcR3 in Postmortem Samples
The evaluation of 47 patients' postmortem serum showed the presence of DcR3 in 25 (53.2%) of 47 samples. The average concentration among positive samples across all cohorts was 0.75 ± 0.3 ng/mL (range: 0.17-3.47 ng/mL). Figure 3 shows the number of DcR3-positive patients among the four cohorts, as well as the average serum concentration and margin of error for each group. Analysis of variance shows no statistical significance of circulating DcR3 levels between the four cohorts (P = 0.63).
Overall DcR3 Levels in Serum Samples
Decoy Receptor 3 Levels as an Indicator of Sepsis
Within the culture-positive cohort, nine (69%) of 13 serum samples contained detectable levels of DcR3. The average concentration of the positive samples was 0.67 ± 0.29 ng/mL (range: 0.26-1.7 ng/mL), with an overall concentration from all culture-positive sepsis samples of 0.43 ± 0.25 ng/mL (range: 0-1.7 ng/ mL). When compared to the control group, a cutoff value of 0.26 ng/mL produces the greatest sensitivity of 64% and a specificity of 73%. When factoring in 
Sepsis Versus Carcinoma by DcR3 Levels
When compared to each other, there is no statistical significance in the level of circulating DcR3 between patients who die due to complications of severe or metastatic carcinoma (average concentration 0.53 ± 0.57 ng/mL, range: 0-3.47 ng/mL) and those who die from culture-positive sepsis (average concentration 0.43 ± 0.25 ng/mL, range: 0-1.7 ng/mL; P = .90).
Effect of Postmortem Interval on DcR3 Levels
It was theorized that the length of time between death and subsequent autopsy may have affected circulating DcR3 levels in the serum. Review of the patients' records showed an overall average time before autopsy of 27.6 ± 39.7 hours (range: 3-284.5 hours). Averages among the four cohorts were relatively similar (Table 1) except for the carcinoma cohort, which had an average time before autopsy of 42.1 ± 70.8 hours (range: 5-284.5 hours). To determine the probability that time between death and autopsy affected serum DcR3 levels, the total time of each sample was divided into three categories: less than 12 hours, between 12 and 24 hours, and greater than 24 hours. It was then compared to whether DcR3 was detected (positive or negative) in the serum. A χ 2 test was then performed. It indicated that an increased time before autopsy had a negative effect on the overall probability that DcR3 would be detectable in serum (P = .038; Figure 4) .
DISCUSSION
Sepsis is a difficult diagnosis to make, especially in the postmortem setting. Although bacterial culture is the gold standard for diagnosis, it can be difficult 
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to obtain clean, noncontaminated results after death. In light of this, alternative adjunct diagnosis methods, such as biomarkers like DcR3, warrant further research. In clinical settings, DcR3 appears to have good sensitivity and moderate specificity in cases of sepsis. One study suggested a cutoff value of 1.65 ng/ mL resulted in 100% sensitivity and 97.8% specificity, versus a normal control group. When compared to other inflammatory conditions (Crohn disease and systemic inflammatory response syndrome), both sensitivity and specificity decreased but remained relatively high at greater than 80% (1). A second study produced similar results with sepsis sensitivity of 95.8% and specificity of 94.9% at a cutoff value of 2.23 ng/mL (7). In our study, a cutoff value of 0.26 ng/ mL produced a sensitivity of 64% and a specificity of 73% when comparing culture-positive sepsis patients to the control group. This drop in overall sensitivity and specificity compared to previous studies may be due to the control cohort's composition. Although the control cohort did not have any signs of underlying sepsis or carcinoma, the group is not considered to be healthy overall, as they are deceased. The majority of the control group consisted of individuals whose deaths were related to cardiovascular disease. This is due to the composition of cases performed at this institution where samples are available for retrospective research purposes (mostly medical cases). There is a general paucity of literature concerning DcR3 levels in cardiovascular disease states so the confounding nature of these cases is not known. Overall, it was felt that the control cohort best represented real-life scenarios in postmortem investigation. Sensitivity decreased to 58% when the suspected (culture negative) sepsis cohort was added. This is most likely due to the fact that suspected (culture negative) sepsis deaths are typically suspected by a constellation of findings from the clinical history and autopsy. They are generally considered exclusionary causes of death. 
When compared to other known causes of increased levels of circulating DcR3, such as carcinoma, some clinical studies have found significant variation in DcR3 levels between disease entities. One of these studies compared sepsis values of DcR3 to values seen in renal cell carcinoma patients. They found 100% sensitivity and 89.6% specificity at a cutoff value of 1.99 ng/mL (1). In our study, circulating DcR3 levels in serum showed no statistical significance between the carcinoma and culture-positive sepsis cohorts. Decoy receptor 3 levels are known to vary among different types of carcinomas with the highest levels seen in urothelial carcinoma, breast carcinoma, pancreatic carcinoma, colorectal carcinoma, gastrointestinal carcinoma, and carcinomas of the female reproductive system (3). Carcinomas with lymphangiogenesis and lymph node metastasis have also shown general increases in circulating DcR3 levels (3). The carcinoma cohort in this study had the widest range of detectible DcR3 levels (0.26-3.47 ng/mL), with the highest levels seen in patients with breast and urothelial carcinomas. These differences in DcR3 levels seen in the carcinoma cohort, align with published descriptions of variation among carcinomas, and suggest that specificity between sepsis and carcinoma may not be as definitive when a variety of carcinomas are examined.
Finally, in the postmortem interval, the body continues to metabolize and break down compounds. This is best exemplified by the metabolism of illicit drugs after deaths caused by overdose. In this study, we wished to examine whether an increased time prior to autopsy negatively affected the probability of detecting DcR3 in postmortem serum. When all patients with detectable DcR3 were divided into three groups based on time after death before autopsy (less than 12 hours, 12-24 hours, and greater than 24 hours), it was found that the probability of having a negative DcR3 level increased, as the time preceding autopsy increased (P = .038). The half-life of DcR3 is reported to be approximately 20 minutes; thus, once all cellular function ceases, DcR3 levels will inevitably decrease dramatically (8) . This is important when considering DcR3 as a viable biomarker in forensic investigation, given that its practicality after 24 hours postmortem is difficult to assess.
CONCLUSION
The use of DcR3 as a biomarker of sepsis has begun to gain interest in the clinical world since its discovery two decades ago. As several studies have shown, DcR3 may be a viable biomarker of sepsis in the antemortem realm, but its use in postmortem sepsis testing has not been adequately investigated. This study shows that when it comes to postmortem testing, DcR3 shows less sensitivity and specificity with a relatively short window for proper testing. Overall, this is a pilot study with relatively small cohorts. Further investigation with larger cohorts and the elimination of variation within cohorts (fewer types of carcinomas, controls using healthy accidental deaths, etc) is recommended to better understand decoy receptor 3's role in the postmortem setting.
